Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.

Cheng-Maw HoChih-Hsin LeeMing-Chia LeeJun-Fu ZhangJann-Yuan WangRey-Heng HuPo-Huang Lee

Published in: BMC cancer (2018)

Compared with other significant risk and protective factors for HCC, ACEI or ARB use in the HBV and HCV cohorts was not associated with adequate protective effectiveness under standard dosages and may not be completely safe.

Keyphrases

angiotensin converting enzyme
angiotensin ii
vascular smooth muscle cells
hepatitis b virus
hepatitis c virus
randomized controlled trial
systematic review
liver failure
cross sectional
human immunodeficiency virus